SCHEMBL206341

SCHEMBL206341

Cc1c(Br)ccc(C(=O)O)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPRS1 P07814 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
CYP1A2 P05177 1/20 0.39
MYC P01106 5/20 0.39
RXFP1 Q9HBX9 1/20 0.38
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
HAAO P46952 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29562032 1.00 EPRS1 (0.40) EPRS1KDM4EASPHKDM8CYP1A2
SCHEMBL30172016 0.84 CYP1A2 (0.39) EPRS1KDM4EASPHKDM8CYP1A2
SCHEMBL1511662 0.84 CYP1A2 (0.39) EPRS1KDM4EASPHKDM8CYP1A2
SCHEMBL31690101 0.84 SMN1; SMN2 (0.33) EPRS1ALDH1A1ALOX15
SCHEMBL30880334 0.82 DGAT1 (0.47) KDM4EALDH1A1
SCHEMBL149886 0.82 DGAT1 (0.47) KDM4EALDH1A1
SCHEMBL1251359 0.81 CYP1A2 (0.44) EPRS1KDM4ECYP1A2MYCRXFP1
SCHEMBL3540940 0.81 CYP1A2 (0.44) KDM4EASPHKDM8CYP1A2LCK
SCHEMBL16035010 0.79 SOS1 (0.44) KDM4EMYCNOTUMALDH1A1
SCHEMBL10662412 0.79 KDM4E (0.42) KDM4EASPHKDM8CYP1A2MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103382187-A 3-chloro-7(5)-bromo-benzo-isoxazole compounding method SYNTHESIS MED SHANGHAI CO LTD 2013-11-06 CN claimed
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
US-20260132121-A1 INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF ODYSSEY THERAPEUTICS INC (US) 2026-05-14 US disclosed
US-12624018-B1 Inhibitors of RIPK2 and medical uses thereof ODYSSEY THERAPEUTICS, INC. (US) 2026-05-12 US disclosed
US-20260070897-A1 INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION UNIV VANDERBILT (US) 2026-03-12 US disclosed
EP-4622970-A1 INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2025-10-01 EP disclosed
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents ASTRAZENECA AB (SE) 2025-09-09 US disclosed
US-12291521-B2 Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction VANDERBILT UNIVERSITY (US) 2025-05-06 US disclosed
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 US disclosed
US-20080300243-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. 2008-12-04 US disclosed
EP-1954132-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2008-08-13 EP disclosed
CN-101184734-A Compounds and methods for treating cell proliferation disorders KINEX PHARMACEUTICALS LLC (US) 2008-05-21 CN disclosed
EP-1853269-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2007-11-14 EP disclosed
WO-2007100758-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-09-07 WO disclosed
WO-2006093832-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2006-09-08 WO disclosed
US-20060194801-A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same EVOTEC AG (DE) 2006-08-31 US disclosed
EP-0882725-B1 QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO LTD (JP) 2002-12-18 EP disclosed
US-6025370-A METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TOYAMA CHEMICAL CO., LTD. (JP) 2000-02-15 US disclosed
EP-0882725-A1 QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents MCL1, TP53, CCNA2 EPRS1 1805/4885KDM4E 2870/4885ASPH 3249/4885
US-20060194801-A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same TRPV1, TRPA1, TRPV2 EPRS1 3668/4885KDM4E 4112/4885ASPH 1708/4885
US-20260070897-A1 INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM1, GRM2, GRM3 EPRS1 2027/4885KDM4E 2500/4885ASPH 2560/4885
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 EPRS1 959/4885KDM4E 1322/4885ASPH 2310/4885
US-20260132121-A1 INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF RIPK1, RIPK2, RIPK4 EPRS1 3074/4885KDM4E 2182/4885ASPH 4733/4885
US-20080300243-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same TRPV1, TRPA1, TRPV2 EPRS1 3668/4885KDM4E 4112/4885ASPH 1708/4885
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 EPRS1 3451/4885KDM4E 3515/4885ASPH 3884/4885
US-12291521-B2 Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction GRIK4, GRM4, GRIK3 EPRS1 1427/4885KDM4E 1863/4885ASPH 2715/4885
US-12624018-B1 Inhibitors of RIPK2 and medical uses thereof RIPK2, RIPK1, RIPK4 EPRS1 4303/4885KDM4E 3070/4885ASPH 4687/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT EPRS1 2170/4885KDM4E 3064/4885ASPH 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.